636 related articles for article (PubMed ID: 22187047)
1. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
Lee H; Sturgeon SA; Jackson SP; Hamilton JR
Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
4. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.
Vretenbrant K; Ramström S; Bjerke M; Lindahl TL
Thromb Haemost; 2007 Mar; 97(3):417-24. PubMed ID: 17334509
[TBL] [Abstract][Full Text] [Related]
5. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
7. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of platelet activation and development of antiplatelet agents].
Cazenave JP; Gachet C; Lanza F
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of platelet activation by thrombin: a short history.
De Candia E
Thromb Res; 2012 Mar; 129(3):250-6. PubMed ID: 22137742
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.
Derian CK; Damiano BP; Addo MF; Darrow AL; D'Andrea MR; Nedelman M; Zhang HC; Maryanoff BE; Andrade-Gordon P
J Pharmacol Exp Ther; 2003 Feb; 304(2):855-61. PubMed ID: 12538843
[TBL] [Abstract][Full Text] [Related]
11. Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus formation.
Münzer P; Borst O; Walker B; Schmid E; Feijge MA; Cosemans JM; Chatterjee M; Schmidt EM; Schmidt S; Towhid ST; Leibrock C; Elvers M; Schaller M; Seizer P; Ferlinz K; May AE; Gulbins E; Heemskerk JW; Gawaz M; Lang F
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):61-71. PubMed ID: 24233488
[TBL] [Abstract][Full Text] [Related]
12. PAR3 is a cofactor for PAR4 activation by thrombin.
Nakanishi-Matsui M; Zheng YW; Sulciner DJ; Weiss EJ; Ludeman MJ; Coughlin SR
Nature; 2000 Apr; 404(6778):609-13. PubMed ID: 10766244
[TBL] [Abstract][Full Text] [Related]
13. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
Holinstat M; Voss B; Bilodeau ML; McLaughlin JN; Cleator J; Hamm HE
J Biol Chem; 2006 Sep; 281(36):26665-74. PubMed ID: 16837456
[TBL] [Abstract][Full Text] [Related]
14. Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
Kuijpers MJ; Megens RT; Nikookhesal E; Feijge MA; De Mey JG; oude Egbrink MG; van Giezen JJ; Heemskerk JW
Thromb Haemost; 2011 Dec; 106(6):1179-88. PubMed ID: 22071958
[TBL] [Abstract][Full Text] [Related]
15. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
[TBL] [Abstract][Full Text] [Related]
16. Platelet protease-activated receptor antagonism in cardiovascular medicine.
Wiisanen ME; Moliterno DJ
Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation.
Burke FM; Warnock M; Schmaier AH; Mosberg HI
Chem Biol Drug Des; 2006 Nov; 68(5):235-8. PubMed ID: 17177882
[TBL] [Abstract][Full Text] [Related]
18. Both the high affinity thrombin receptor (GPIb-IX-V) and GPIIb/IIIa are implicated in expression of thrombin-induced platelet procoagulant activity.
Dicker IB; Pedicord DL; Seiffert DA; Jamieson GA; Greco NJ
Thromb Haemost; 2001 Oct; 86(4):1065-9. PubMed ID: 11686325
[TBL] [Abstract][Full Text] [Related]
19. A dual thrombin receptor system for platelet activation.
Kahn ML; Zheng YW; Huang W; Bigornia V; Zeng D; Moff S; Farese RV; Tam C; Coughlin SR
Nature; 1998 Aug; 394(6694):690-4. PubMed ID: 9716134
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
Wielders SJ; Bennaghmouch A; Reutelingsperger CP; Bevers EM; Lindhout T
J Thromb Haemost; 2007 Mar; 5(3):571-6. PubMed ID: 17166251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
